Novo Nordisk Signs Deal with OpenAI
Danish pharmaceutical company Novo Nordisk, producer of the well-known anti-obesity drugs Ozempic and Wegovy, declared on Tuesday a "strategic partnership" with OpenAI to expedite the creation of new medications.
Similar to other pharmaceutical companies, Novo Nordisk is relying significantly on artificial intelligence to evaluate new therapies and vaccines and expedite their market launch at a lower cost.
Novo Nordisk stated that the collaboration would position it "at the leading edge of AI innovation in healthcare and assist the company in delivering new and improved treatment options to patients more quickly."
The financial specifics of the partnership were not revealed.
According to OpenAI CEO Sam Altman, this partnership with Novo Nordisk will enhance their scientific discovery, optimize global operations, and reshape the future of patient care.
Pilot initiatives will commence in various business sectors "with complete integration anticipated by the end of 2026," the announcement stated.
Novo Nordisk has experienced a decline in its share price as it has cut prices to respond to increasing competition, especially from its American competitor Eli Lilly.
Also Read: 5 Latest CHRO Appointments in Global Corporations
It has also encountered rivalry from imitation versions of Ozempic and Wegovy, and last month it pursued legal action against the US telehealth chain Hims & Hers after the chain started offering so-called compounded versions of the injectable.
Also Read: How This Techie Turned Visa Struggles into Startup Success
At present, the drug development process can exceed ten years, and among ten candidates, merely one succeeds in making it to the market.
As per industry experts, the typical research and development expense for introducing a new medication to the market is approximately $2 billion.
Also Read: Christie Names Michael Phipps as President & CEO
Novo Nordisk is a prominent international healthcare firm established in 1923, based in Denmark, and recognized for promoting progress to combat serious chronic ailments, especially diabetes and obesity. It generates approximately 50percent of global insulin, employs more than 68,000 individuals, and is currently the most valuable company in Europe. Main products are Wegovy and Ozempic.